Recon: J&J forecasts $2.5B in 2021 COVID vaccine sales; South Africa’s Biovac to make Pfizer-BioNTech vaccine in 2022
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy